Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1989 2
1990 1
1991 2
1996 2
2000 1
2013 3
2016 1
2018 1
2021 3
2022 3
2024 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial.
Smadja DM, Massonnaud CR, Philippe A, Rosa M, Luneau S, Rauch A, Peiffer-Smadja N, Gagneux-Brunon A, Poissy J, Gruest M, Ung A, Pourcher V, Raffi F, Piroth L, Bouiller K, Esperou H, Delmas C, Belhadi D, Diallo A, Saillard J, Dechanet A, Mercier N, Dupont A, Lescure FX, Goehringer F, Jaureguiberry S, Danion F, Tolsma V, Cabie A, Courjon J, Leroy S, Mootien J, Mourvillier B, Gallien S, Lanoix JP, Botelho-Nevers E, Wallet F, Richard JC, Reuter J, Gaymard A, Greil R, Martin-Blondel G, Andrejak C, Yazdanpanah Y, Burdet C, Diehl JL, Hites M, Ader F, Susen S, Mentré F, Dupont A; Discovery Study Group. Smadja DM, et al. Sci Rep. 2025 Apr 24;15(1):14348. doi: 10.1038/s41598-025-95122-7. Sci Rep. 2025. PMID: 40274842 Free PMC article. Clinical Trial.
Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial.
Terzić V, Miantezila Basilua J, Billard N, de Gastines L, Belhadi D, Fougerou-Leurent C, Peiffer-Smadja N, Mercier N, Delmas C, Ferrane A, Dechanet A, Poissy J, Espérou H, Ader F, Hites M, Andrejak C, Greil R, Paiva JA, Staub T, Tacconelli E, Burdet C, Costagliola D, Mentré F, Yazdanpanah Y, Diallo A; DisCoVeRy Study Group. Terzić V, et al. Clin Infect Dis. 2024 Aug 16;79(2):382-391. doi: 10.1093/cid/ciae170. Clin Infect Dis. 2024. PMID: 38552208 Free PMC article. Clinical Trial.
Is Thrombocytopenia an Early Prognostic Marker in Septic Shock?
Thiery-Antier N, Binquet C, Vinault S, Meziani F, Boisramé-Helms J, Quenot JP; EPIdemiology of Septic Shock Group. Thiery-Antier N, et al. Crit Care Med. 2016 Apr;44(4):764-72. doi: 10.1097/CCM.0000000000001520. Crit Care Med. 2016. PMID: 26670473
Caloric requirements in burned patients.
Pfisterer M, Lessire H, Kleine R, Nolte G, Puchstein C. Pfisterer M, et al. Among authors: lessire h. Acta Anaesthesiol Belg. 1989;40(3):187-94. Acta Anaesthesiol Belg. 1989. PMID: 2510446 Review.
Comparison of European ICU patients in 2012 (ICON) versus 2002 (SOAP).
Vincent JL, Lefrant JY, Kotfis K, Nanchal R, Martin-Loeches I, Wittebole X, Sakka SG, Pickkers P, Moreno R, Sakr Y; ICON and SOAP investigators; SOAP investigators. Vincent JL, et al. Intensive Care Med. 2018 Mar;44(3):337-344. doi: 10.1007/s00134-017-5043-2. Epub 2018 Feb 15. Intensive Care Med. 2018. PMID: 29450593 Free PMC article.
Profile of the risk of death after septic shock in the present era: an epidemiologic study.
Pavon A, Binquet C, Kara F, Martinet O, Ganster F, Navellou JC, Castelain V, Barraud D, Cousson J, Louis G, Perez P, Kuteifan K, Noirot A, Badie J, Mezher C, Lessire H, Quantin C, Abrahamowicz M, Quenot JP; EPIdemiology of Septic Shock (EPISS) Study Group. Pavon A, et al. Among authors: lessire h. Crit Care Med. 2013 Nov;41(11):2600-9. doi: 10.1097/CCM.0b013e31829a6e89. Crit Care Med. 2013. PMID: 23963127
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, Diallo A, Lê MP, Peytavin G, Staub T, Greil R, Guedj J, Paiva JA, Costagliola D, Yazdanpanah Y, Burdet C, Mentré F; DisCoVeRy Study Group. Ader F, et al. Lancet Infect Dis. 2022 Feb;22(2):209-221. doi: 10.1016/S1473-3099(21)00485-0. Epub 2021 Sep 14. Lancet Infect Dis. 2022. PMID: 34534511 Free PMC article. Clinical Trial.
20 results